Axon Enterprise, Inc. (NASDAQ:AXON) Given Average Rating of “Moderate Buy” by Analysts

Shares of Axon Enterprise, Inc. (NASDAQ:AXON) have earned an average recommendation of “Moderate Buy” from the fourteen analysts that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $604.67.

Several research firms have recently issued reports on AXON. Needham & Company LLC reaffirmed a “buy” rating and set a $600.00 price objective on shares of Axon Enterprise in a research report on Wednesday, February 26th. Robert W. Baird increased their price target on shares of Axon Enterprise from $600.00 to $800.00 and gave the company an “outperform” rating in a research note on Friday, December 6th. TD Cowen initiated coverage on shares of Axon Enterprise in a report on Wednesday, January 8th. They set a “buy” rating and a $700.00 price objective on the stock. Craig Hallum cut shares of Axon Enterprise from a “buy” rating to a “cautious” rating in a report on Monday, March 10th. Finally, JMP Securities reiterated an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 4th.

Axon Enterprise Price Performance

AXON stock opened at $558.41 on Friday. The business’s 50-day moving average is $592.10 and its two-hundred day moving average is $539.60. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The firm has a market capitalization of $42.79 billion, a P/E ratio of 144.29, a P/E/G ratio of 5.17 and a beta of 1.12. Axon Enterprise has a 1 year low of $273.52 and a 1 year high of $715.99.

Insider Activity at Axon Enterprise

In related news, Director Jeri Williams sold 307 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $552.72, for a total value of $169,685.04. Following the sale, the director now owns 1,627 shares of the company’s stock, valued at approximately $899,275.44. This trade represents a 15.87 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jeffrey C. Kunins sold 1,035 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $624.47, for a total transaction of $646,326.45. Following the transaction, the insider now directly owns 124,243 shares of the company’s stock, valued at approximately $77,586,026.21. This trade represents a 0.83 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,792 shares of company stock valued at $1,087,843 over the last ninety days. Corporate insiders own 5.70% of the company’s stock.

Institutional Trading of Axon Enterprise

Several institutional investors have recently modified their holdings of AXON. Public Sector Pension Investment Board grew its position in Axon Enterprise by 19.2% in the third quarter. Public Sector Pension Investment Board now owns 3,104 shares of the biotechnology company’s stock worth $1,240,000 after buying an additional 500 shares during the last quarter. CIBC Asset Management Inc grew its holdings in shares of Axon Enterprise by 9.2% in the 3rd quarter. CIBC Asset Management Inc now owns 10,578 shares of the biotechnology company’s stock worth $4,227,000 after acquiring an additional 895 shares during the last quarter. Soros Capital Management LLC acquired a new stake in shares of Axon Enterprise during the third quarter worth $630,000. Friedenthal Financial lifted its holdings in shares of Axon Enterprise by 961.7% during the fourth quarter. Friedenthal Financial now owns 1,359 shares of the biotechnology company’s stock valued at $808,000 after purchasing an additional 1,231 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its position in shares of Axon Enterprise by 33.1% in the 3rd quarter. Principal Financial Group Inc. now owns 136,302 shares of the biotechnology company’s stock valued at $54,466,000 after purchasing an additional 33,869 shares during the period. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.